Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR, NMPA) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

Evaluating the Safety and Efficacy of dNerva Lung Denervation System in Patients With COPD

NCT: NCT07051707 · RECRUITING

NCT IDNCT07051707
StatusRECRUITING
Start Date2026-02-24
Completion2029-10-31

Brief Summary

The dNerva Lung Denervation System is one-time treatment intended to improve breathing in Chronic Obstructive Pulmonary Disease (COPD) patients on standard medical care. The purpose of this study is to confirm the safety and efficacy of the Nuvaira Lung Denervation System in the treatment of COPD.

Frequently Asked Questions

What is Evaluating the Safety and Efficacy of dNerva Lung Denervation System in Patients With COPD?

Evaluating the Safety and Efficacy of dNerva Lung Denervation System in Patients With COPD is a clinical trial registered under NCT07051707. Current status: RECRUITING.

What is the status of NCT07051707?

The current status of NCT07051707 (Evaluating the Safety and Efficacy of dNerva Lung Denervation System in Patients With COPD) is: RECRUITING.

When did Evaluating the Safety and Efficacy of dNerva Lung Denervation System in Patients With COPD start?

Evaluating the Safety and Efficacy of dNerva Lung Denervation System in Patients With COPD started on 2026-02-24.

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.

↑